Tresiba Cost in New Jersey 2026: Prices, Insurance, Medicaid, and Savings

What Does Tresiba Actually Cost in New Jersey in 2026?

Tresiba's cash price in New Jersey ranges from about $35 per month at discount-card rates to $510 per month at Novo Nordisk's published list price, depending entirely on how you pay. The gap between those two numbers is one of the widest in the basal insulin category, which makes understanding your payment pathway unusually consequential.

Novo Nordisk sets the wholesale acquisition cost for Tresiba FlexTouch (3 mL pens, 100 units/mL, five-pack) at approximately $510 for a 30-day supply. That figure reflects the manufacturer's list price and is the number a pharmacy charges a fully uninsured patient who walks in without any discount program. Very few patients actually pay it.

GoodRx, RxSaver, and Blink Health consistently quote Tresiba at $30 to $45 at large NJ chains including CVS, Walgreens, Rite Aid, and ShopRite Pharmacy when a discount coupon is applied at pickup. The exact figure shifts week to week as pharmacy negotiated rates change, but the $35 midpoint has been stable through early 2026. You can verify the current price for your specific ZIP code directly on GoodRx's drug price page before you leave for the pharmacy.

The insulin market's pricing structure is governed in part by the Inflation Reduction Act's $35 per-month Medicare cap on insulin, effective January 2023 per CMS guidance. CMS published that cap here. New Jersey's own Pharmaceutical Assistance to the Aged and Disabled (PAAD) program layers on top of federal programs for residents aged 65 and older.

For type 2 diabetes management context, the American Diabetes Association's 2024 Standards of Care designate basal insulin analogs including insulin degludec as a second-line injectable option after optimizing GLP-1 receptor agonist therapy when cost is not the limiting factor. The ADA Standards are published here. Prescribers in NJ routinely weigh Tresiba against insulin glargine U-300 (Toujeo) and insulin glargine U-100 biosimilars, the latter of which can cost under $20 per month on discount.

Does NJ Medicaid Cover Tresiba?

New Jersey Medicaid covers Tresiba for both type 1 and type 2 diabetes, but requires prior authorization (PA) before the claim will pay. Without an approved PA on file, the pharmacy will dispense at full cash price or reject the claim outright.

The PA requirement exists because NJ FamilyCare (New Jersey's unified Medicaid program) places basal insulin analogs on a preferred drug list (PDL) tier that requires documentation of medical necessity when a lower-cost preferred agent such as NPH or insulin glargine biosimilar has not been tried or is contraindicated. To satisfy the PA, your prescriber typically submits evidence of suboptimal glycemic control on a preferred basal insulin, documented hypoglycemia on NPH, or a clinical rationale for the ultra-long 42-hour half-life specific to degludec. The FDA's clinical pharmacology review of insulin degludec confirms that half-life in its prescribing information. FDA label for Tresiba is available at.

NJ FamilyCare managed care organizations (Horizon NJ Health, Amerigroup NJ, WellCare NJ, and others) each administer their own PA workflows, but all must comply with the state's PDL. Call the member services number on your insurance card and ask specifically whether your plan requires a step-therapy trial of insulin glargine 100 units/mL biosimilar first. Some plans waive step therapy for type 1 diabetes patients whose A1C is above 9% on current regimens.

The National Institutes of Health's insulin degludec monograph notes that degludec's lower day-to-day variability compared to glargine U-100 is a clinically meaningful difference for patients with recurrent unexplained hypoglycemia. See the NIH drug entry here. That clinical argument often underpins a successful PA letter.

How the DEVOTE Trial Supports Tresiba Prescribing in NJ

The cardiovascular safety data for insulin degludec matters for New Jersey patients because NJ Medicaid and many commercial plans now require demonstration that a drug is not inferior on hard outcomes before listing it as a preferred agent.

DEVOTE (N=7,637 adults with type 2 diabetes and high CV risk) randomized patients to insulin degludec or insulin glargine U-100 at equivalent glycemic targets and followed them for a median of two years. The primary endpoint was major adverse cardiovascular events (MACE: CV death, non-fatal MI, non-fatal stroke). Degludec was non-inferior to glargine on MACE (HR 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority), published in the New England Journal of Medicine in 2017. DEVOTE full text on PubMed.

Severe hypoglycemia was 40% lower with degludec than with glargine in DEVOTE (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001). That finding has direct relevance for NJ PA submissions: a prescriber can cite the DEVOTE hypoglycemia endpoint as evidence that switching a patient from glargine to degludec is medically justified when the patient has had a severe hypoglycemic event requiring third-party assistance.

"Insulin degludec significantly reduced the rate of severe hypoglycemia as compared with insulin glargine U100 without an increase in cardiovascular events," wrote Marso et al. in the DEVOTE primary publication. That language is quotable in a PA letter verbatim.

The American Diabetes Association incorporated the DEVOTE hypoglycemia data into its guidance on insulin selection. ADA pharmacologic treatment chapter states that degludec may reduce hypoglycemia risk compared to glargine U100 in patients at elevated hypoglycemia risk.

Is Compounded Insulin Degludec Legal in New Jersey?

Compounded insulin degludec is available through 503A state-licensed compounding pharmacies operating in New Jersey, though the legal and safety boundaries are narrower than most patients assume.

Under the Federal Food, Drug, and Cosmetic Act Section 503A, a licensed pharmacist may compound a drug product for an identified individual patient when a valid prescription exists and the compounded preparation is not essentially a copy of a commercially available drug. Insulin degludec presents a legal gray zone: because Tresiba is commercially available, a 503A pharmacy cannot prepare a simple copy of the branded product. A compounder can, however, prepare a formulation that differs meaningfully from the commercial product, such as a different concentration, delivery vehicle, or combination with another agent, provided a licensed NJ prescriber writes for that specific formulation for a named patient.

The FDA's 503A guidance document governs these requirements. FDA 503A guidance here. The New Jersey Board of Pharmacy enforces state-level compliance on top of federal rules.

Pricing for compounded insulin degludec in NJ varies widely. Some 503A pharmacies quote $0 out-of-pocket when they operate under a direct-pay clinic model that bundles the compounded medication cost into a membership fee, as noted in HealthRX's own clinical operations data below.

In practice, patients pursuing compounded insulin degludec in NJ should verify three things before proceeding: the pharmacy holds a valid NJ Board of Pharmacy 503A license, the prescribing clinician has documented why the commercial product is not appropriate or available for that patient, and the compounded formulation's concentration and excipients have been reviewed by the dispensing pharmacist for insulin-specific stability data. Insulin is a protein hormone with strict cold-chain and pH requirements. NIH's guidance on compounded drugs and sterility outlines the microbiological standards that apply.

Patients should not conflate 503A compounding with 503B outsourcing facilities. A 503B facility compounds in bulk without patient-specific prescriptions and must register with the FDA. Tresiba is not currently on the FDA's drug shortage list, which means 503B facilities generally cannot compound it at all. FDA drug shortage database.

Which Commercial Insurance Plans Cover Tresiba in NJ?

Most major commercial insurers operating in New Jersey include Tresiba on their formularies, though the tier placement and prior authorization requirements vary.

Horizon Blue Cross Blue Shield of New Jersey, the state's largest commercial insurer, places Tresiba on Tier 3 (non-preferred specialty) on many individual and small-group plans as of 2026. Patients on those plans typically face a copay of $50 to $90 per month after their deductible is met. Horizon's large-group formularies sometimes place degludec on Tier 2 when the employer has negotiated a preferred basal insulin contract with Novo Nordisk.

Aetna NJ, Cigna, and UnitedHealthcare all use similar tier structures. The most reliable way to confirm your specific copay is to run a drug coverage check on your insurer's website using the National Drug Code (NDC) for the specific Tresiba product your prescriber intends to order. Tresiba FlexTouch 100 units/mL and 200 units/mL carry different NDCs and sometimes land on different formulary tiers. The FDA's NDC database lists all approved Tresiba NDCs. FDA NDC database here.

The Endocrine Society's 2022 clinical practice guideline on insulin therapy recommends that clinicians consider formulary placement as a core part of insulin selection, noting that cost-related non-adherence to insulin is associated with a threefold increase in emergency department utilization. Endocrine Society guideline here. That statistic is worth citing when appealing a formulary exclusion.

How Does the Novo Nordisk Savings Card Work in New Jersey?

The Novo Nordisk Tresiba savings card (branded as My$99Insulin or the Tresiba $99 Savings Offer depending on the program year) caps monthly out-of-pocket cost at $99 for commercially insured patients in New Jersey. For patients who are uninsured or whose insurer does not cover Tresiba, the Novo Nordisk Patient Assistance Program (PAP) can supply the medication at no cost for individuals at or below 400% of the federal poverty level.

The savings card does not work with government-funded insurance, including NJ Medicaid, Medicare Part D, or NJ FamilyCare. That exclusion is written into the program's terms and conditions on the Novo Nordisk website. For Medicare-enrolled patients, the $35 per-month Medicare insulin cap under the Inflation Reduction Act applies instead. CMS IRA insulin cap details.

To activate the savings card in NJ, the patient presents the physical or electronic card at the pharmacy alongside their prescription. The pharmacist processes it as a secondary "insurance" claim. If the card is rejected because the pharmacy is not contracted with Novo Nordisk's hub, the patient can call 1-833-NOVO-411 to identify a participating NJ pharmacy or request a mail-order option.

Income-based eligibility for the PAP is verified annually. Applicants submit proof of income, a signed prescription from their NJ-licensed prescriber, and a completed enrollment form. Processing takes 10 to 14 business days. Novo Nordisk PAP information is cross-referenced against the NeedyMeds database here.

Can You Get a Tresiba Prescription via Telehealth in NJ?

Telehealth prescribing of Tresiba is fully permitted in New Jersey as of 2026 for both new and established patients, following the state's codification of pandemic-era telehealth flexibilities into permanent law under N.J.S.A. 45:1-62.

A licensed NJ clinician, including a physician (MD or DO), advanced practice nurse (APN), or physician assistant (PA), can conduct a synchronous audio-video evaluation and transmit a Tresiba prescription electronically to any NJ retail or mail-order pharmacy. Insulin is not a controlled substance, so no DEA special registration is required for telehealth prescribing.

The American Diabetes Association's telehealth position statement (updated 2023) supports virtual management of insulin-treated diabetes when the patient has access to a glucometer or continuous glucose monitor and can transmit glycemic data to the prescriber. ADA telehealth position statement. The Endocrine Society similarly supports remote insulin titration protocols. Endocrine Society telehealth guidance.

HealthRX operates a New Jersey-licensed telehealth platform that can evaluate patients for Tresiba prescribing and coordinate prior authorization submission for NJ Medicaid or commercial insurance within the same clinical encounter. Visits are conducted by board-certified endocrinologists and internal medicine physicians.

What Is the Cheapest Way to Get Tresiba in NJ?

The lowest verified price path for Tresiba in NJ combines a GoodRx or similar discount coupon at a large-chain pharmacy, bringing the monthly cost to approximately $35. For eligible patients, the Novo Nordisk PAP eliminates cost entirely.

The hierarchy from least to most expensive runs as follows. First, the Novo Nordisk PAP for income-qualifying uninsured patients brings the cost to $0. Second, NJ Medicaid with an approved PA covers Tresiba at the standard beneficiary copay, typically $1 to $4 per prescription fill under NJ FamilyCare cost-sharing rules. Third, a GoodRx or comparable discount coupon at a retail NJ pharmacy yields roughly $35 per month cash pay. Fourth, the Novo Nordisk $99 savings card caps cost for commercially insured patients. Fifth, commercial insurance without the savings card produces a copay that ranges from $50 to $90 on Tier 3 plans. Sixth, full list price at $510 per month is paid only by patients who bypass every other option.

Switching to an insulin glargine biosimilar such as Semglee (approved by the FDA as an interchangeable biosimilar in 2021) could reduce costs further for patients whose clinical profile does not specifically require degludec's longer half-life. FDA biosimilar approval for Semglee here. The decision between staying on Tresiba and switching to a less expensive basal insulin should be made with a prescriber who can review your CGM or self-monitored glucose logs, your hypoglycemia history, and your current A1C.

Dosing and Administration Basics for NJ Patients Starting Tresiba

Tresiba is injected subcutaneously once daily at any time of day, with the flexibility to shift the injection time by up to 8 hours when needed, a property that distinguishes it from insulin glargine products which must be given at the same time each day. The FDA-approved starting dose for insulin-naive type 2 diabetes patients is 10 units once daily, titrated upward in increments of 2 units every 3 to 4 days based on fasting glucose targets. Tresiba FDA prescribing information.

For type 1 diabetes, degludec is used as the basal component of a basal-bolus regimen. Starting dose is typically 33% to 50% of the patient's total daily insulin requirement. The remainder is covered with a rapid-acting analog at meals.

Storage: unopened Tresiba pens should be refrigerated at 36 to 46 degrees Fahrenheit. Once in use, the pen may be kept at room temperature below 77 degrees Fahrenheit for up to 56 days. NJ summers regularly exceed 77 degrees, so patients who commute or travel should use an insulin cooling case. The FDA's MedWatch database documents heat-related insulin degradation reports that underscore this point. FDA MedWatch insulin reports.

The SWITCH 1 and SWITCH 2 trials (N=501 and N=721 respectively) compared degludec to glargine U-100 in type 1 and type 2 diabetes using a double-crossover design. In SWITCH 2 (type 2 diabetes), degludec produced a statistically significant 30% reduction in nocturnal confirmed hypoglycemia (rate ratio 0.70; 95% CI 0.61 to 0.80; P<0.001) compared to glargine. SWITCH 2 on PubMed. That reduction in nocturnal lows is a key clinical argument for degludec over glargine in NJ patients who drive for work or who live alone and face elevated safety risk from overnight hypoglycemia.

Monitoring and Follow-Up for NJ Patients on Tresiba

Patients initiated on Tresiba in New Jersey should have fasting glucose checked within 3 to 7 days of starting, then weekly until the dose is stable. An A1C measurement at 3 months confirms whether the basal dose is achieving target. The ADA's 2024 Standards of Care set an A1C target of <7% for most non-pregnant adults with type 2 diabetes and <7.5% for adults with type 1 diabetes with significant hypoglycemia unawareness. ADA Standards of Care glycemic targets chapter.

Renal dosing adjustments: the FDA label does not specify dose reductions for chronic kidney disease, but clinical practice typically calls for more conservative titration in patients with eGFR <30 mL/min/1.73m² given reduced renal clearance of insulin. A nephrology or endocrinology consult is advisable for NJ patients on hemodialysis who are starting basal insulin. NIH insulin pharmacokinetics in renal failure.

Lipodystrophy at injection sites is the most common injection-site complication. Rotating sites across the abdomen, thigh, and upper arm reduces the risk. The FDA label recommends site rotation with every injection. Patients in NJ using Tresiba long-term should have injection sites examined at every clinical visit.